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Abstract
Allergy is a complex disease that is likely to involve dysregulated CD4+ T cell activation. Here we propose a novel
methodology to gain insight into how coordinated behaviour emerges between disease-dysregulated pathways in
response to pathophysiological stimuli. Using peripheral blood mononuclear cells of allergic rhinitis patients and controls
cultured with and without pollen allergens, we integrate CD4+ T cell gene expression from microarray data and genetic
markers of allergic sensitisation from GWAS data at the pathway level using enrichment analysis; implicating the
complement system in both cellular and systemic response to pollen allergens. We delineate a novel disease network
linking T cell activation to the complement system that is significantly enriched for genes exhibiting correlated gene
expression and protein-protein interactions, suggesting a tight biological coordination that is dysregulated in the disease
state in response to pollen allergen but not to diluent. This novel disease network has high predictive power for the gene
and protein expression of the Th2 cytokine profile (IL-4, IL-5, IL-10, IL-13) and of the Th2 master regulator (GATA3),
suggesting its involvement in the early stages of CD4+ T cell differentiation. Dissection of the complement system gene
expression identifies 7 genes specifically associated with atopic response to pollen, including C1QR1, CFD, CFP, ITGB2, ITGAX
and confirms the role of C3AR1 and C5AR1. Two of these genes (ITGB2 and C3AR1) are also implicated in the network linking
complement system to T cell activation, which comprises 6 differentially expressed genes. C3AR1 is also significantly
associated with allergic sensitisation in GWAS data.
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Introduction
Asthma, allergic rhinitis and atopic eczema are common allergic
diseases with increasing prevalence world-wide. In atopic allergies,
allergen induces immunoglobulin E (IgE) formation, which becomes
attached to mast cells in a process mediated by CD4+ T cells and
known as sensitization [1]. CD4+ T cells are activated by antigen
presenting cells (APCs) and differentiate into distinct lineages that
are involved in different types of immune responses. In particular,
the type 2 T helper (Th2) lineage has a distinct cytokine profile and is
associated with allergic reactions. The mechanism by which
activated CD4+ T cells are committed to the Th2 lineage is poorly
understood, but is thought to involve the dysregulated activation of
CD4+ T cells by APCs in allergic individuals [2–5]. Therefore,
research on the T cell activation pathway is needed to elucidate its
interactions with other pathogenic pathways leading to abnormal
CD4+ T cell differentiation.
Studying differences in genetic variation between cases and
controls, using the genome wide association study (GWAS) design,
has led to identification of genetic variation associated with several
allergic diseases [6–8]. Despite this, it remains challenging to
identify the molecular mechanisms underlying allergic disease, and
to link these mechanisms with disease pre-disposing genetic
variation. Pathway analyses of GWAS have implicated entire
pre-defined pathways in disease pathogenesis [9–12], but have yet
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to consider resolving the cell-type associated with the identified
pathways and to map these novel pathways on to disease
pathophysiology.
One way of mapping GWAS pathway results onto the
molecular mechanism of disease is to examine the molecular
connections with other disease-dysregulated pathways [13–16] and
pathway sub-networks [17,18]. By capitalizing on gene expression
studies [2–5], GWAS results can be integrated with pathways
activated in CD4+ T cells to identify pathogenic pathways at cell
level. On the other hand, with the exception of loss-of-function
mutations, the observation that complex disease genes have
increased tendency for their product to interact and be co-
expressed [19,20] indicates that pathogenic pathways are likely to
be significantly linked and coordinated with each other at
molecular level. This has support on the observation that disease
protein hubs tend to be co-localized in the protein interaction
network and enriched for genetic markers of disease [21]. In this
context, the integration of protein networks and co-expression
networks with genotype data has great potential in identifying
dysregulated pathways, and elucidating subnetwork connectivities
that have been disrupted in disease.
We propose a novel methodology to identify pathogenic
pathways and we explore the hypothesis that pathways causally
linked or involved in disease (e.g. T cell activation in atopy) are
interconnected and biologically coordinated, and that this
coordination is dysregulated in response to pathophysiological
stimuli. We provide a method to select pathways that show a
convergent cellular and systemic response to pathophysiological
stimuli (Figure 1). We apply this approach to a GWAS on pollen
sensitisation, which we integrate with gene expression and
supernatant IL-13 protein levels of CD4+ T cells from allergic
individuals and controls cultured with and without allergen. First,
we integrate at pathway level gene expression [2] and GWAS data
[6] under enrichment analysis; selecting the pathways optimally
enriched in both types of data (Pareto-efficient p-values) and
ranking them by co-enrichment significance (Figure 1a, see
methods). Using this approach, we identify the complement
system pathway. Dissection of the complement system gene
expression finds 7 genes specifically associated with atopic
response. Second, our analysis integrates protein interaction
databases with pathway annotation databases using correlation
analysis to delineate a molecular network (INter-PAthway
inteRactions Network, INPAR-N) between the prioritized path-
way (complement system) and the pathways previously implicated
in or causally linked to disease (T cell activation pathway)
(Figure 1b). Applying this method, we identify a novel network
linking the complement system to the T cell activation pathways
that is significantly enriched for protein interactions and genes
exhibiting correlated expression; suggesting a tight biological
coordination. The biological coordination among genes interact-
ing between these pathways is dysregulated in allergic patients but
only in response to pollen allergen. We then assess the impact of
this inferred network on clinical outcome and thereby identify new
susceptibility genes. Third, we study the role of this network on T
cell differentiation using gene expression and protein markers of
this biological process (Figure 1c). We find that the expression of
the genes in the novel disease network have high predictive power
for the Th2 cytokine profile (IL-4, IL-5, IL-10, IL-13) and for the
Th2 master regulator (GATA3). Moreover, the expression of the
INPAR-N genes is more correlated with these gene sets than the
complement system or T cell activation; suggesting its involvement
in Th2 priming is probably stronger than its originating pathways.
Fourth, since an in vivo perturbation analysis of the disease network
genes is unfeasible, we map their roles on disease pathophysiology
via an in silico drug target network analysis (Figure 1d). We assess the
reproducibility of the genes differentially expressed and pathways
enriched using a replication gene expression dataset that we meta-
analyse with our discovery dataset. Our approach suggests that the
complement system is likely to modulate atopic CD4+ T cell
activation and that the network of genes linking these pathways
regulate T cell differentiation, putatively through a mechanism
involving T cell danger signal receptors, among other complement
receptors; this implies a disruption of the coordination between
innate and adaptive immune system in allergic response.
Materials and Methods
Gene expression data
Microarray hybridization of discovery and replication samples
was conducted using different Illumina microarray chips. Data
analysis was conducted on the discovery dataset blind to the
replication dataset. In the discovery dataset, gene expression
microarray analysis of allergen-challenged CD4+ T cells was
performed in samples from 20 Swedish patients with Seasonal
Allergic Rhinitis (SAR, see abbreviations and acronyms in
Table S1 in Text S1) recruited outside the pollen season (birch
pollen-induced allergic rhinitis) according to previously described
criteria [22] (analyses using these data have been previously
published [21]). Peripheral blood mononuclear cells were cultured
in the presence or absence of allergen. IL-13 was measured from
the supernatant, and CD4+ T cell were isolated as previously
described [2]. The resulting gene expression data after quality
control of the assay consists of 13 diluent and 19 allergen
stimulated samples (13 paired samples that were analysed as
unpaired data).
The replication dataset was obtained from the MultiMod project
(http://www.multimod-project.eu/). Microarray analysis was per-
formed in CD4+ T cells in samples from 21 Swedish SAR patients
recruited outside the pollen season from Sahlgrenska University
hospital in Go¨teborg, cultured in presence and absence of allergen
according to previously described criteria (analyses using these data
have been previously published) [2,23]. The resulting gene
expression data of the assay consists of 21 pairs of samples, one
diluent and one allergen stimulated for each pair (that were analysed
as unpaired data). Gene expression datasets were submitted to GEO
with study accession: GSE18574.
Genome Wide Association Study
The Northern Finland Birth Cohort 1966 (NFBC1966) is a
cohort of 12231 individuals born in the provinces of Oulu and
Lapland [24]. In 1997 (age 31), 8463 alive were sent postal
questionnaires and invited to clinical examination with a 71%
response rate (N = 6033). DNA was extracted from blood and
5753 individuals were successfully genotyped using Illumina
HumanCNV370-Duo chip. The data was imputed to ,2.5
million SNPs using NCBI HapMap II CEU build 35 version 21
after pre-filtering SNPs (genotyping call rate .95%, HWE p-
value .1024, minor allele frequency .1%) using IMPUTE [25]
with confidence call of R2.0.5. Genotype and phenotype data
were submitted to dbGaP with study accession: phs000276.v1.p1.
Allergic sensitivity to timothy grass pollen was assessed by skin
prick test. The longest weal and perpendicular weal were recorded
after ten minutes. Participants with a mean weal reaction of at
least 3 mm were considered sensitized. Participants with a positive
reaction to a negative control (diluent of allergen extracts) or a
negative reaction to a positive control (histamine dihydrochloride,
10 mg/mL) were excluded, leaving 693 grass sensitized cases and
3726 controls.
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The phenotype-genotype association was conducted using the
QUICKTEST software [26]. These analyses were adjusted for sex
and relevant principal components determined by a stepwise
regression using backward elimination. These data have been
previously published as part of a meta-analysis in [6] but have
never been analysed separately. This is the first pathway analysis of
our GWAS on grass sensitisation.
Functional annotation analysis and gene set enrichment
of gene expression data
Gene set enrichment analysis (GSEA) [9], hypergeometric test-
based pathway enrichment analysis [27], and enrichment maps
[28] were performed using the R package HTSanaliseR [29]. An
enrichment map is a network plot that aids in the identification of
mutually overlapping pathways. Functional annotation analysis
was performed using DAVID (http://david.abcc.ncifcrf.gov/) [30]
setting the filtered microarray gene list as background, and
reporting results for category GOTERM_BP_3 with EASE = 0.01
and count = 4. Molecular pathway definitions for the T cell
activation process and complement system were downloaded from
IPA (IngenuityH Systems, www.ingenuity.com) and their enrich-
ment for differentially expressed genes was analysed under
hypergeometric test and odds ratio analysis. Multiple comparison
adjustment used Benjamini-Hochberg q-values method [31] for
controlling the false discovery rate (FDR) in both GSEA and
Figure 1. Analysis strategy for identifying coordinated behaviour between disease dysregulated pathways. Disease genes (e.g. FYN,
SRC and LCK) that are targeted by anti-inflammatory drugs and associated with biomarkers of disease-relevant biological processes provide insight
into the biological function resulting from the coordinated behaviour of both dysregulated pathways identified by integrating GWAS data [6] and
gene expression data [2] (a) Co-enrichment analysis of Pareto-efficient pathways identify pathways that are involved in the systemic response to
pollen sensitisation and involved in the cellular response to pollen allergen challenge; in this study, complement system was the top hit. (b)
Coordination between disease dysregulated pathway (CD4+ T cell activation) and the pathway identified in the disease context (Complement
system) is studied using inter-pathway interactions network analysis (INPAR-N). (C) Regression and correlation enrichment analysis is applied to test if
the INPAR-N is associated with markers of the biological process involved in the disease onset, i.e. Th2 priming. (D) The genes of the INPAR-N are
mapped to disease pathophysiology using drug target network analysis.
doi:10.1371/journal.pone.0074821.g001
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Hypergeometric tests as this is the default procedure for DAVID
and HTSanaliseR packages.
Pathway enrichment analysis of genome-wide
association study data
To explore potentially new pathways associated with pollen
allergic sensitisation in the GWAS dataset, we applied a modified
version of the gene set enrichment analysis approach termed meta-
analysis gene-set enrichment of variants associations (MAGENTA)
[11]. Genes in the genome were mapped to a single SNP with the
lowest p-value within a 50 kb upstream or 50 kb downstream
window.
Meta-analysis methodology
Differential gene expression results on discovery and replication
dataset were combined via a meta-analysis of the log ratio of
means [32]. A gene is considered to be reproducibly differentially
expressed [33] if the meta-analysis p-value is smaller than both the
p-value obtained in the discovery dataset and the Bonferroni
corrected significance level (a= 0.05/42559 = 1.261026) Pathway
and gene ontology enrichment analysis on discovery and
replication datasets were combined using a Mantel-Haenszel
meta-analysis of the enrichment odds ratio using the R package
rmeta [34]. Fixed effects heterogeneity was assessed by statistical
tests setting a cut-off p.0.2 but no test was below this threshold.
Integration of statistical tests under different null
hypothesis for co-enrichment analysis
We propose an approach to establish an association between a
series of biological experiments under the constraint that all
hypotheses need to be jointly true to corroborate the validity of the
conclusion. That is, we need to test if the disjunction of all null
hypotheses is false to reject a global null hypothesis. Let Hk denote
that the null hypothesis of experiment k is true. Then the global
null hypothesis Hg is given by:
Hg~
[
k
Hk
The p-value of the global null hypothesis, which is the chance of
any false positives, can be obtained assuming independence by:
pg~1{Pk (1{pk)
Dropping independence assumption, a conservative estimate
can be obtained using the Sidak-corrected maximum of the p-values,
which is related to the Familywise error rate:
pg~ 1{(1{max (p1,p2, . . . ,pk))
k
This global p-value is applied to make global inferences from
testing different hypothesis in distinct datasets and is used to
estimate the co-enrichment and the co-association between
GWAS and gene expression results.
Pathway co-enrichment analysis for data integration
from multiple levels of biological organization
We have developed a multi-criteria decision theoretic approach
to integrate at pathway-level gene expression and GWAS
enrichment analyses. The method selects pathways optimally
enriched based on enrichment p-values in both GWAS and gene
expression (Pareto efficient pathways) that satisfy nominal signif-
icance constraints. A pathway is Pareto efficient if there is no other
pathway that optimizes at least one of the objectives (GWAS or
gene expression p-value) and is smaller or equal to all other
objectives [35]. The outline of the approach is:
1. Select a consensus list of enriched pathways on gene expression
data that are simultaneously significant under GSEA and
Hypergeometric tests after correction for multiple comparisons.
2. Conduct a GSEA enrichment on full GWAS using MAGEN-
TA.
3. Plot the enrichment p-value for gene expression (the maximum
of GSEA and Hypergeometric test) against the enrichment p-
value of the nominal GSEA test on GWAS using MAGENTA
(This plot maps the objective space of Pareto analysis).
4. Identify the pathways that are Pareto-efficient and that are
significantly enriched at both levels of biological organization.
5. Integrate GWAS and gene expression significance levels under
co-enrichment analysis.
6. Select Pareto-efficient pathways having higher co-enrichment
significance and larger effect size based on odds ratio of gene
expression enrichment.
Identification of disease-related genetic subnetworks
using inter-pathway interactions (INPAR) analysis
By leveraging systemic properties of disease networks and
disease genes, and articulating them with genetic variation and
gene expression, we developed a method to identify coordinated
behaviour between disease dysregulated pathways and to delineate
the corresponding disease network linking these pathways. The
method consists of 5 steps:
1. Select a disease dysregulated pathway based on the hypothesis
being tested and on the disease context. In this case, one of the
fundamental hypotheses underlying the architecture of the
experiment is CD4+ T cell activation (after allergen challenge)
is dysregulated and involved in abnormal Th2 priming and
allergy onset.
2. Identify a pathway associated with disease at cellular and
systemic level using co-enrichment of Pareto-efficient path-
ways.
3. Identify the genes with direct molecular interactions linking
both pathways using a curated database (connectivity data
from Ingenuity database setting a filter to include only evidence
from empirical experiments): the INPAR network (INPAR-N).
4. Test if the INPAR-N network is enriched for direct and
indirect protein-protein interactions using DAPPLE [36].
Proteins that are involved in a common mechanism or disease
[36–38] tend to be highly connected. This step is necessary as
the protein interaction graph between pathways tends to be
sparsely connected compared to within pathways and thus the
INPAR-N might not be densely connected.
5. Test if the INPAR-N network is enriched for genes exhibiting
correlated gene expression.
6. Test if the INPAR-N is co-enriched with genetic markers and
with genes differentially expressed in response to a disease-
associated pathophysiological stimulus (in this case, in response
to pollen allergen challenge).
Complement System Drives Atopic T Cell Activation
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e74821
Only direct molecular interactions are selected initially to
produce the INPAR-N. In a second stage, an additional layer of
molecules that directly interact with the INPAR-N is explored
outside the scope of the INPAR-N definition. In this paper, the
second stage consists of a bipartite network of genes and drug
molecules directly targeting the INPAR-N.
Regression and gene set correlation enrichment analysis
of the Th2 priming biomarkers
To assess the disease network (INPAR-N) gene expression
predictive ability for the Th2 priming biomarkers, we have
conducted a multiple linear regression analysis of the IL-13 protein
levels and a multivariate regression analysis of the IL-4, IL-5, IL-6,
IL-10, IL-13 gene expression, estimating the predictivity for each
model using seven fold cross validation. Statistical significance was
assessed using (multivariate regression) Wilks L statistic and
(multiple regression) Q2y.
To test the INPAR-N enrichment for genes exhibiting
correlated gene expression, we have computed the Spearman
correlations among INPAR-N genes and the Spearman correla-
tions between INPAR-N and the remainder genes. We compared
the mean absolute correlation of both sets using the Welsh t-test
and a permutation test. We assessed the predictive power of the
correlation between INPAR-N genes using the area under the
curve (AUC) of the Receiver Operating Characteristic (ROC). We
extended this concept to assess the co-expression enrichment
between pathways. We tested the mean absolute correlations
between INPAR-N gene expression and (i) the IL-13 protein levels,
(ii) the Th2 cytokine profile (IL-4, IL-5, IL-10, IL-13) and (iii) the
Th2 master regulator (GATA3). The contrast group was always the
remainder genes not including INPAR-N. We repeated this
analysis with the gene expression of the complement system and
CD4+ T cell activation pathways.
Cumulative analysis of significant correlation differences
between cases and controls for eliciting dysregulated
biological coordination within and between pathways
To test the hypothesis of dysregulated biological coordination in
response to pathophysiological stimuli, we computed the observed
number of nominally significant correlation differences between
cases and controls, i.e.
X
Viwj I(p(r
cases
ij {r
control
ij )va). Correla-
tion differences computed within or between gene sets were
assessed for statistical significance (p) using the R statistical
package. The expected number of significant correlation differ-
ences was calculated as N 6 a, where N is the number of
correlations tested and a= 0.05. The binomial test with probabil-
ity of success Pr = 0.05 was applied to calculate the significance of
the difference between observed and expected number of
dysregulated correlations, the same calculation based on the t-
test was conducted using the disruption rate statistics (#observed
significant differences/N) yielding very similar results as expected
thus only results based on binomial test are reported.
Drug target network analysis of the INPAR-N for in vivo
delineation of gene function and impact on the
pathophysiology
The subset of genes that interact between the complement
system and T cell activation pathways were assessed for potential
drug targets using the IPA database. Analysis of the drug
physiological effects was exploited to hint on the function of
individual targeted genes in the context of disease states (i.e. via
consensus of physiological effects). The integration of the
individual physiological contributions enables the mapping of the
disease network on the pathophysiology of the disease. Together
with the functional annotation characterization of the genes in the
context of disease, this analysis can aid the design of new
treatments.
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Results
Co-enrichment analysis of Pareto-efficient pathways
shows that complement system is associated with CD4+
T cell response to pollen allergen challenge and involved
in the pathogenesis of pollen allergic sensitisation
In order to integrate at pathway level cellular and systemic
response to pollen allergen, we combined pathways enriched for
differentially expressed genes in atopic CD4+ T cell response to
pollen with pathways enriched for genetic markers associated with
atopic pollen response to a skin prick test using data from a
genome wide association study (Figure 2).
First, we conducted a differential gene expression analysis
(Figure S1 showing permutation test and multiple comparison
correction). We identified the KEGG pathways and gene ontology
(GO) terms enriched using a consensus between GSEA and the
Hypergeometric test (Table S2 and Table S3 in Text S1; see
Methods S1 in Text S1). Several pathways and biological process
categories related to complement system, immunity, cell signalling
and cell proliferation were associated with the response to allergen.
Enrichment maps analysis showed several mutually overlapping
KEGG pathways and GO terms related to cell cycle and cell
proliferation, while immune related terms such as T cell
proliferation, complement system and immune response are less
overlapped and thereby less likely to be redundant (Figure 2, panel
A and B).
To identify novel clinically-relevant pathways for pollen allergic
sensitisation, we conducted an enrichment analysis under full
GWAS of pollen allergic sensitisation using MAGENTA (Ta-
ble S4 in Text S1). Using annotations from BIOCARTA, Gene
Ontology (GO), Ingenuity, Kyoto Encyclopaedia of Genes and
Genomes (KEGG), Protein Analysis Through Evolutionary
Relationships (PANTHER) databases, we found that ERK/
MAPK Signalling, Protein-lipid modification, VEGF Signalling,
and Complement System pathways were significantly enriched
(a,0.05, FDR ,0.25) for SNPs associated with pollen skin prick
test responses.
To identify pathways that are clinically relevant for pollen
allergic sensitisation and have transcriptional differences that are
likely to be causal, versus collateral effects, we identified the
pathways optimally enriched in both GWAS and gene expression
(with Pareto-efficient p-values) and ranked them by their co-
enrichment p-value based on combined analysis of GWAS and
gene expression enrichment p-values (see methods) (Figure 2,
panel C and D). Complement-system related KEGG pathway and
GO terms had convergent cellular and systemic response to pollen
allergen challenge. In both annotations, complement system was
Pareto-efficient within nominal significance bounds, had larger
enrichment odds ratio and higher co-enrichment significance and
therefore was prioritized for further analysis.
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To confirm that our findings are reliable and reproducible, we
have conducted multiple confirmatory and validation analyses (see
Methods S1 in Text S1). Briefly, we used a replication gene
expression dataset and found that complement system-related
KEGG pathways and GO terms were reproducibly enriched in
gene expression (KEGG, p = 7.861027; GO term, p = 5610212)
(Table S2 and Table S3 in Text S1). To confirm that the
complement system enrichment is (i) independent of the annota-
tion database, (ii) independent of the pathway/gene set definition,
and (iii) robust to changes on the thresholds of significance to
declare genes differentially expressed, we have performed addi-
tional functional annotation analyses and replicated these results
using DAVID (p = 4.661023, Table S5 and Table S6 in Text S1)
and Ingenuity Pathway AnalysisTM (IPA) definition of the
complement system pathway (p = 8.761027, Table S7 and
Methods S1 in Text S1). Sensitivity analysis of the cut-offs for
detecting differentially expressed genes shows that enrichment
results of the IPA’s complement system was consistent and robust
(Methods S1 in Text S1 (statistical sensitivity analysis) and
Figure S2). The pathway was significantly enriched on a wide
range of FDR cut-offs (0.01,FDR,0.1) even at very low
thresholds on effect size (|Log2 r|.0.6; p = 0.03, OR = 2.0).
IPA enrichment results were reproduced in the replication dataset
(p = 9.261023, OR = 3.7) and meta-analysis of the odds ratio
Figure 2. Pareto-efficient co-enrichment integration of gene expression and GWAS data at pathway level. Panel (A) and (B) show the
gene expression enrichment maps of the KEGG pathways and GO terms respectively. The degree of gene set overlapping is measured using the
Jaccard index and depicted by line thickness. Complement system-related KEGG pathways and GO terms are less overlaped and less likely to be
redundant. Panel (C) and (D) depict the KEGG and GO terms plot of objectives for the multicriteria enrichment of gene expression and GWAS data.
Pathways are represented as circles with diameter proportional to the odds ratio of the gene expression enrichment and colour coded according to
the co-enrichment p-value, pathways closer to the upper right corner are optimally associated at cellular and systemic level with pollen allergen
response. Complement system-related pathways and GO terms are Pareto-efficient because they lie on the Pareto front within the significant bounds,
suggesting that they may play a role on T cell response to allergen (pollen) and on the pathophysiology of allergic sensitisation with grass pollen.
doi:10.1371/journal.pone.0074821.g002
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increased the significance of the primary result (p = 4.5610211,
OR = 7.2, Table S7 in Text S1). Co-enrichment analysis of the
IPA’s complement system definition was also significant
(pg = 4.6610
23). In the remainder of this paper, we use the IPA
definition of the complement system biological process because it is
the most comprehensive and specific, as opposed to KEGG that
also includes the coagulation cascade and GO terms that focus on
partial subsets of the complement system pathway.
To identify individual genes associated with both response to
pollen allergen and atopic sensitisation, we have analysed gene
expression and GWAS data of the complement system. Interest-
ingly, 16 complement system genes had SNPs significantly (FDR
,0.05) associated with pollen allergic sensitisation, including: C2,
C4A, CFB, C6, CFHR3, CFHR1, C3AR1 (Table S8 in Text S1).
Meta-analysis of the discovery and replication datasets identified 8
genes differentially expressed at microarray-wide significance level:
C1QBP, C1QR/CD93, C3AR1, C5R1/C5AR1, DF/CFD, ITGAX,
ITGB2, PFC/CFP (Table S9 in Text S1). Remarkably, these genes
were all down regulated except C1QBP. As the role of C1QBP,
CFD, CFP, ITGB2 and ITGAX is not yet established in CD4+ T
cell allergic response, we conducted an additional experiment
comparing the response to pollen in allergic patients and controls.
In this experiment, all genes differentially expressed showed
consistent direction of effect and most genes were significantly
differentially expressed (except C1QBP); suggesting they are
biomarkers of the dysregulated allergic response (Table 1 and
Table S10 in Text S1).
Overall, our results show that the complement system pathway
is involved in the atopic sensitisation to pollen, putatively via the
atopic response to pollen of CD4+ T cells. We identified 7 genes of
the complement system that are specific markers of the atopic
response to pollen in CD4+ T cells; including C3AR1, which is
also associated with atopic sensitisation to pollen.
Inter-pathway interactions analysis delineates disease
network between complement system and T cell
activation that modulate response to pollen allergen
challenge
As disease genes tend to cluster together in the protein
network neighbourhood [19–21], we hypothesize that disease
pathways are significantly linked and coordinated with each
other. In particular, as dysregulated CD4+ T cell activation is
putatively involved in abnormal Th2 differentiation, we hypoth-
esize that the T cell activation pathway is significantly linked and
coordinated with the complement system. In order to explore this
hypothesis, we conducted an analysis of the protein network
between the T cell activation pathway and the complement
system and identified a disease network (inter-pathway interac-
tions network, INPAR-N) of 19 genes interacting between both
pathways (Figure 3).
To test if the gene products of this disease network are likely to
be involved in a common mechanism, we have conducted a
protein-protein interaction analysis using DAPPLE [36]. Overall,
the INPAR-N is more directly as well as indirectly connected than
can be explained by chance despite the fact that the INPAR-N
genes were selected from two distinct pathways (Table S11 in
Text S1). Individual gene products were also significantly inter-
connected in the INPAR-N (a= 0.05) except MOG, AGER,
STAT4, and C3AR1. The gene C3AR1 is marginally not significant
(p = 0.05) because it interacts with 1 protein only, C3, which is also
part of the INPAR-N (Figure S9). In addition, we found this
subnetwork significantly more enriched for genes exhibiting
correlated gene expression than complement system or T cell
activation alone (Table 2), suggesting a tight biological coordina-
tion between these pathways.
To test if this network was activated in response to allergen
challenge, we conducted an enrichment analysis of the gene
expression. The results show a significant enrichment
Table 1. Complement system and INPAR-N genes differentially expressed in the atopic response to pollen.
Gene Discovery dataset Replication dataset
Meta-
analysis GWAS data
Pathway Symbol P Log2Ratio p Log2Ratio P Chr Pos Best
p-val
Complement system CFD ,1E-16 22.11 ,1E-16 22.67 ,1E-16 19 868114 4.40E-02
(CS) C5AR1 9.50E-04 20.88 ,1E-16 22.03 1.70E-14 19 47770937 6.30E-02
CFP ,1E-16 21.31 1.00E-05 20.18 1.50E-12 23 NA* NA*
ITGAX 2.00E-03 20.85 7.00E-06 20.49 9.50E-08 16 31361922 2.20E-02
CD93 5.10E-04 20.91 1.00E-02 20.55 1.20E-06 20 23036048 8.90E-02
Overlap CS/INPAR-N C3AR1 9.00E-06 21.26 3.00E-06 20.83 3.60E-13 12 8208243 2.00E-03
ITGB2 3.10E-02 20.51 ,1E-16 21 2.10E-11 21 46313956 3.00E-02
INPAR-N FYN ,1E-16 1.02 4.80E-02 0.29 6.60E-14 6 111999581 3.70E-03
STAT4 1.10E-04 0.58 1.30E-05 0.66 1.20E-13 2 192011105 3.40E-03
CD81 3.80E-04 20.5 ,1E-16 20.74 1.40E-13 11 2356768 2.30E-01
FYN ,1E-16 20.95 1.10E-02 20.28 4.20E-10 6 111999581 3.70E-03
ITGAL 8.20E-03 0.52 3.20E-04 0.35 8.20E-08 16 30518095 1.50E-01
FYN 9.20E-04 0.6 4.90E-03 0.4 1.20E-07 6 111999581 3.70E-03
On GWAS data, genes were mapped to the most significant (best) SNP within a 50Kbp window of the gene. Only complement system genes that are specific markers of
atopic response to pollen are shown.
*Not available because only autosomes were analysed. Properdin (CFD) is on the sex chromosome X.
doi:10.1371/journal.pone.0074821.t001
Complement System Drives Atopic T Cell Activation
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e74821
(p = 5.261023, OR = 7.6, Table S7 in Text S1). We reproduced
these results in a replication dataset and meta-analysis of both
datasets increased the significance of the primary analysis
(p = 2.361024, OR = 5.2; Table S7 in Text S1). We applied the
same analysis to the T cell activation pathway and confirmed its
involvement in the atopic response to pollen (pmeta,10
216,
OR = 7.6; Table S7 in Text S1). To test whether our disease
network is clinically relevant for pollen sensitisation and to
determine whether the allergen response-associated transcriptional
differences observed are likely to be causal, versus collateral effects,
we conducted a co-enrichment analysis of the INPAR-N genes.
The results show a strong and significant enrichment for SNPs
associated with pollen allergic sensitisation (OR = 3.89,
p = 6.2610211) and this association is stronger than that for T
cell activation (OR = 1.06, p = 0.29) or complement system
(OR = 1.74, p = 2.061023) alone.
To identify individual genes associated with both response to
pollen allergen and atopic sensitisation, we have analysed gene
expression and GWAS data of the disease network. Interestingly,
several INPAR-N genes had SNPs significantly associated with
pollen allergic sensitisation (Table 1 and Table S12 in Text S1)
and were differentially expressed (Table 1 and Table S13 in
Text S1). These include: C3AR1, FYN, and STAT4 (Figure 3a).
Overall, our results show that the complement system is tightly
coordinated with T cell activation, suggesting that both pathways
are involved in a common mechanism in allergy. The disease
network linking both pathways is associated with pollen sensitisa-
tion and with CD4+ T cell response to pollen in allergic patients.
Figure 3. Inter-pathway interactions analysis identifies disease network linking complement system to CD4+ T cell activation. (A)
INPAR network has 19 genes that link Complement system to CD4+ T cell activation. Blue nodes correspond to genes involved in T cell activation
while red nodes correspond to genes involved in the complement system. (B) Drug target network analysis of the INPAR-N showing that several
immunosuppressive drugs target the INPAR-N network genes, particularly the Src family of tyrosine kinases, including Src, Fyn, Lck. (C) Allergens
trigger the innate immune system that in turn triggers the adaptive immune system. INPAR-N includes complement system proteins that interact
with T cell membrane proteins.
doi:10.1371/journal.pone.0074821.g003
Complement System Drives Atopic T Cell Activation
PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e74821
The strongest association with allergy in the network linking both
pathways is C3AR1. The molecular network re-constructed
(Figure 3a) from the protein interaction network, gene expression
and genetic markers of allergic sensitisation suggest a route linking
the adaptive and innate immune system that putatively modulate
T cell activation in allergy (Figure 3c).
Biological coordination between T cell activation and the
complement system is dysregulated in allergic
individuals response to pollen
In order to explore the hypothesis that dysregulated biological
coordination is involved in allergic response to pollen, we analysed
the intra and inter-pathway correlations in cases and controls on
the replication dataset (as the discovery dataset only has cases). We
characterize dysregulated biological coordination as a significant
correlation difference between cases and controls (Table 3). In the
response to allergen, we have found a significant number of
correlation differences within INPAR-N, T cell activation and
between T cell activation and the complement system. Interest-
ingly, T cell activation already showed perturbed correlation
profile in response to diluent challenge. We also studied the
antithetical concept of biological coordination by estimating the
mean absolute correlation in cases and controls (Table S13 in
Text S1). Consistently, we have found a higher mean absolute
correlation in the controls response to pollen when looking at
genes in the INPAR-N or T cell activation pathways. Interestingly
no differences were found between controls and allergic patients
subject to diluent challenge; suggesting that the disruption of the
biological coordination was likely caused by the pathophysiological
stimulus (pollen challenge).
In order to test if the observed coordination disruption is a
consequence of the inactivation of control T cells, we conducted a
principal component analysis of the gene expression of cases and
controls looking at the following relevant gene sets independently:
T cell activation pathway, complement system, INPAR-N as well
as the set of genes that were differentially expressed on the
discovery dataset in response to pollen (Figure S3). We found, in
all gene sets, that controls and cases response to pollen are
clustered together and are significantly different from the response
to diluent, suggesting that T cells were activated in both cases and
Table 2. Geneset correlation enrichment analysis shows that INPAR-N is more enriched for genes exhibiting correlated gene ex-
pression and is more strongly associated with IL-13 protein levels, Th2 cytokines and Th2 master regulator than T cell activation or
complement system.
Mean absolute correlation ROC Analysis
(Spearman) 95% Confidence Interval
p-value
Pathway Response Vector Pathway Null t-test AUC p-value lower Upper
(data type) (permutation)
INPAR-N IL-13 0.36 0.3 0.045 0.62 0.049 0.53 0.74
(protein levels) (0.005)
Th2 cytokine profile 0.24 0.2 0.0107 0.57 0.005 0.52 0.61
(gene expression) (0.008)
GATA3 0.36 0.2 0.005 0.68 0.001 0.58 0.79
(gene expression) (0.0004)
INPAR-N 0.31 0.2 6.22E-09 0.59 1.71E-07 0.55 0.62
(gene expression) (,2.2e-16)
Complement system IL-13 0.3 0.3 0.12 0.55 0.16 0.47 0.56
(protein levels) (0.07)
Th2 cytokine profile 0.22 0.2 0.05 0.52 0.05 0.49 0.55
(gene expression) (0.04)
GATA3 0.29 0.2 0.07 0.58 0.07 0.49 0.67
(gene expression) (0.04)
Complement system 0.23 0.2 1.40E-04 0.52 0.026 0.5 0.54
(gene expression) (,2.2e-16)
T cell activation IL-13 0.33 0.3 3.40E-11 0.62 6.10E-12 0.59 0.66
(protein levels) (4.00E-15)
Th2 cytokine profile 0.23 0.2 4.40E-12 0.54 7.90E-09 0.53 0.55
(gene expression) (,2.2e-16)
GATA3 0.32 0.2 6.20E-12 0.61 7.70E-13 0.58 0.65
(gene expression) (,2.2e-16)
T cell activation 0.26 0.2 ,2.2e-16 0.56 ,2.2e-16 0.553 0.559
(gene expression) (,2.2e-16)
doi:10.1371/journal.pone.0074821.t002
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controls; this finding is also consistent with literature [39,40]. We
also investigated differences in the CD4+ T cell subtypes (Th1,
Th2, Th17 and Treg) by looking at the cytokine profiles of these
subtypes and testing for significant differences between cases and
controls challenged with and without allergen (Figure S4). We
found significant differences in the gene expression of Th2 and to a
lesser extent Th17 cytokine profiles, suggesting a response mainly
driven by Th2 and Th17 subtypes.
Overall, this result suggests that i) the T cell activation is
internally dysregulated, ii) the biological coordination between the
complement system and T cell activation pathway is disrupted in
response to pollen, and iii) the cytokine profile of the CD4+ T cells
is associated with a population of Th2 and Th17 subtypes;
suggesting a link between T cell activation dysregulation and
CD4+ T cell subtype.
Disease network highly predictive of Th2 cytokine profile
and Th2 master regulator
To characterize the influence of INPAR-N gene expression on
Th2 priming and to test whether its impact on CD4+ T cell
differentiation is greater than complement system and T cell
activation, we tested three hypotheses. First, we assessed the
predictivity of IL-13 protein levels, a marker of Th2 CD4+ T cell
subtype, using a regression model of the INPAR-N genes (Table 4
and Figure S8). We found that the INPAR-N gene expression was
highly predictive and significantly associated with the supernatant
levels of this cytokine (Q2y = 0.45, p = 0.001). Spearman correla-
tion analysis found several INPAR-N genes associated with IL-13
protein levels, including FYN, ITGB2 and STAT4 that were also
differentially expressed in response to pollen (Figure S7). Second,
we tested the association of the Th2 cytokine profile and master
regulator with INPAR-N genes using a multivariate regression
having for response vector IL-4, IL-5, IL-6, IL-10, IL-13 and
GATA3 (Table 4); results show that the INPAR-N is highly
predictive of the gene expression levels of the response vector (out
of sample 1-Wilks’ lambda = 0.89, p = 0.0002). Analysis of the
standardized INPAR-N regression coefficients shows that GATA3,
IL-4, IL-5, IL-10, IL-13 are significantly clustered together
(bootstrap test alpha,0.05) while the IL-6 regression coefficient
has almost the reverse pattern of association (Figure 4). Interest-
ingly, in our multivariate model all complement system genes
contribute to downregulate the Th2 cytokines and GATA3
expression (Figure 4). We note that all complement genes
specifically associated with the atopic response to pollen are also
down-regulated. Bi-clustering of the Spearman correlation matrix
between INPAR-N and response vector genes reveals that GATA3
have the strongest association with INPAR-N genes and that IL-6
and IL-10 have almost symmetric association patterns compara-
tively to IL-4, IL-5, IL-13 and GATA3 (Figure S5 and Figure S6).
Third, we show that the INPAR-N is enriched for genes highly
correlated with: i) IL-13 protein levels, ii) Th2 cytokine profile and
iii) Th2 master regulator; both in terms of average absolute
correlation and area under the curve (AUC) of the receiver
operating characteristic (ROC) (Table 2). Moreover, the INPAR-
N correlation enrichment was always larger than complement
system and T cell activation (p = 0.016 using binomial test with
success probability of 0.5). These results suggest INPAR-N
involvement in Th2 priming is probably stronger than its
originating pathways and therefore potentially more relevant for
the disease pathophysiology. This indicates that the coordinated
behaviour between these pathways is likely to play an important
role in the allergic response via CD4+ T cell differentiation.
Drugs targeting the disease network have immune-
suppressive and anti-inflammatory effect in-vivo
To evaluate the physiological role, delineate gene function and
assess whether a molecular intervention on INPAR-N genes can
modify the pathophysiology of the disease, we conducted a drug
target network analysis. We have queried the Ingenuity database
for drugs targeting genes in this network (Table S15 in Text S1)
and generated a bipartite network between drugs and genes
(Figure 3 panel B). INPAR-N genes are targeted by 5 drugs; 4 of
them used in anti-cancer therapy. The consensus physiological
response to these drugs consists of an immunosuppressant effect.
Among these, SRC tyrosine kinase is a target for 3 different drug
molecules. Remarkably, the drug molecule dasatinib targets 3
genes of the INPAR-N, including FYN. Dasatinib may induce
neutropenia along with having potential anti-inflammatory and
immunosuppressive effects [41]. It is known that neutrophilia and
eosinophilia co-occur in allergen induced airway hyperreactivity
(AHR) and are the hallmark of allergic rhinitis and asthma. These
network analyses emphasize that multiple genes and their
interactions are likely to be involved in the inflammatory response.
Conversely, certain genes have a broader impact in the
pathophysiology of allergy. FYN for example, which is targeted
by dasatinib, is highly interconnected with other disease genes in
the INPAR-N, is associated with Th2 cytokine profile, is
differentially expressed in response to pollen allergen and is
associated with atopic sensitisation to pollen.
Table 3. Dysregulated biological coordination in response to allergen challenge.
Allergen Diluent
Correlation differences Correlation differences
Pathway Observed Expected p Observed Expected p N
INPAR-N 25 14 5.1E-03 16 14 4.9E-01 276
Complement System6 T-cell Activation 1054 886 1.9E-08 902 886 5.8E-01 17727
Complement System 72 66 4.5E-01 56 66 2.1E-01 1326
T cell activation 3751 2899 1.1E-54 3423 2899 2.2E-22 57970
INPAR-N inter-pathway 11 7 1.8E-01 4 7 3.4E-01 145
The observed and expected number of nominally significant correlation differences between cases and controls are shown for the response to allergen and diluent.
Number of correlations denoted by N. Entries in bold denote significantly dysregulated gene sets (a= 0.05). Notice: ‘‘Complement System6T-cell Activation’’ denotes
the cross-correlation between the genes of the complement system and the genes of the CD4+ T cell activation pathways.
doi:10.1371/journal.pone.0074821.t003
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Discussion
Previous studies demonstrated that CD4+ T cell counts increase
in nasal mucosa of rhinitis patients after allergen challenge [42].
Nasal biopsies of rhinitis patients showed increased IL-4, IL-5, IL-
13 mRNA expression suggesting a Th2 cytokine profile. In our
experiment, allergen-challenged PBMCs provided an in vitro model
of cell-cell interactions among antigen-presenting cells, CD4+ T
cells and effector cells in allergic inflammation. In order to
understand the mechanisms underlying the response to pollen
allergen challenge, CD4+ T cells of SAR patients were isolated
and gene expression levels were obtained using Illumina micro-
arrays.
Our co-enrichment analysis of gene expression and genetic
variation showed that the complement system was implicated in
the systemic response to pollen sensitisation and in the CD4+ T
cell response to pollen. These results were reproduced in a
replication dataset and meta-analysis of both datasets increased
significance of the primary analysis. This suggests that approaches
that look at GWAS data at pathway level and integrate GWAS
results with gene expression data can uncover new pathways and
genes that would not be identified using a routine GWAS or gene
expression analysis. Our result confirms the role of the comple-
ment system in the immune system homeostasis and disease [43],
in the regulation of adaptive immunity [44], and in T cell
regulation [45]. Previously, complement system has been associ-
ated with allergic rhinitis in gene expression of mucosa biopsies
[46]. Multiple complement system proteins have been found to be
differentially expressed in the nasal lavage fluids of rhinitis
patients, including C3aR and C5aR [47], and after allergen
challenge, C3a and C5a [48]. The identification of the complement
system in the context of T cell activation suggests that
complement-associated danger signals (e.g. C3a and C5a) together
with natural allergen may be involved in priming Th2 cells in
allergy. This is consistent with previous work that implicates C5aR
signal transduction in T cell expansion [49] and complement
regulator factor H [50] in Th2 allergic inflammatory response in a
mouse model. The complement system involvement in other
immune disorders is well documented in the literature. C1, C2, C3,
C4 deficiency and increased levels of C3d (resulting from the
Table 4. Regression analysis shows that the disease network gene expression is predictive of the Th2 differentiation markers.
Target R2y/1-Wilk’s l Q
2
y/1-Wilk’s L Model p-value Q
2
y p-value
IL-13 protein level 0.73 0.45 3E-04 2E-03
Th-2 cytokine profile 0.92 0.89 1E-11 2E-04
doi:10.1371/journal.pone.0074821.t004
Figure 4. Multivariate regression coefficients of INPAR-N on gene expression data of Th2 cytokine profile and master regulator. The
multivariate response vector (y-axis) consists of the Th2 master regulator (GATA3) and the genes involved in the Th2 cytokine profile. The multivariate
predictor vector (x-axis) consists of the subset of the gene products linking complement system to CD4+ T cell activation (INPAR-N). Clustering of
response and predictor variables is statistically significant (a=0.05). There is one group of genes that contribute to increase the expression of the Th2
cytokine profile and another group that is down regulating the response. IL-6 behaves differently from all other cytokines, including GATA3. All
complement system genes contribute to downregulate the response variables.
doi:10.1371/journal.pone.0074821.g004
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breakdown of C3) are associated with Lupus. C3d and C4d levels
are higher in patients with systemic sclerosis; C1q and C2
deficiency as well as increased serum levels of C3a and C5a have
been also related with rheumatoid arthritis [51].
Our gene expression meta-analysis of the complement system
pathway shows that both C3aR and C5aR were downregulated
after allergen challenge in patients. In addition, genetic markers in
C3aR were associated with pollen allergic sensitisation. This is
consistent with previous findings that show in vivo C5aR targeting
during initial allergen exposure can either induce or enhance Th2
adaptive immunity [52] and a knockout asthma mouse model
C5aR (2/2) exhibits excessive IL17A production that drives a
severe asthma phenotype by enhancing Th2 cell-driven pathology
[53,54]. Similarly, knockout mouse model C3aR (2/2) exhibits
exaggerated Th2 response to epicutaneous sensitisation [55] and
allergic asthma [56]. In contrast, pharmacological targeting of C3,
C3a, C5a, C5aR in an established allergic environment showed a
reduction in airway inflammation [52]. Our results extend these
results to an in vitro human cell model of allergen response showing
that complement system plays a role in allergy probably by
regulating differentiation of CD4+ T cell towards Th2 subtype or
by modulating T cell activation. C1QR was down regulated in our
study, previously C1QR1 was found expressed in T cells and when
bound to its primary ligand C1Q produced an antiproliferative
signal, suggesting that it plays a role in T cell activation and
proliferation consistent with our observations [57]. CFP was down
regulated, confirming previous findings that CFP regulate the
activation of the complement system and is secreted by peripheral
blood T cells [58]. We have found complement factor D to be
down regulated. Previous work suggested that CFD may tilt T cell
differentiation towards IFNG secreting effector T cells by
permitting complement activation during APC/T-cell interactions
[59].
Inter-pathway interactions analysis identified a module of genes
co-associated and co-enriched with pollen allergic sensitisation and
T cell activation. The inferred subnetwork allowed us to identify
further disease genes that have smaller differences in expression
levels but that may play an important role in disease [60]. The
network analysis of direct molecular interactions of the module of
genes suggests that the proto-oncogene tyrosine-protein kinase gene (FYN)
together with lymphocyte-specific protein tyrosine kinase (LCK)
play a central role in the cross-talk between T cell activation and
complement system in the allergen response. FYN is highly
interconnected within this module of genes, it is targeted by anti-
inflammatory and immunosuppressive drugs, it is significantly
associated with pollen allergic sensitisation, and it is differentially
expressed in the allergen challenge response. It also reacts with
complement decay accelerating factor CD55. CD55 may suppress
T cell response in the context of inflammation [61] and CD55
deficiency promotes T cell differentiation towards IFNG produc-
ing phenotypes like Th1 [59]. FYN also interacts directly via LCK
and SRC. LCK and SRC react with complement regulatory protein
CD46. The co-stimulation with CD46 is known to drive the
differentiation of CD4+ T cells towards a T-regulatory cell 1
phenotype [62]. T-r1 cells play an active role suppressing
activation of bystander T helper cells and acquire a memory
phenotype. This suggests that complement system might play a
role in allergic response by mediating the differentiation of CD4+
T cells towards Th2 cells via co-stimulation with anaphylatoxins
[63–65] and impairing differentiation towards the protective T-r1
phenotype due to lower levels of CD46. T cells of animals with
FYN 2/2 knockout show impaired proliferation and calcium
mobilization after TCR stimulation [66]. FYN has an active role in
the maintenance of anergy state and blocks IL-2 transcription and
therefore T cell proliferation [67]. FYN is involved in the
mechanism of T cell anergy maintained by a block of the RAS/
MAP kinase pathway [68]. Both Ras and MAPK genes had SNPs
significantly associated with pollen allergic sensitisation. Previous-
ly, FYN was associated with asthma [69]. This suggests that FYN
might be a key mediator of the complement system role on T cell
activation and also on allergic response.
The disease network (INPAR-N) gene expression had strong
predictive power of supernatant IL-13 cytokine protein levels and
of Th2 cytokine gene expression profile consisting of IL-4, IL-5, IL-
6, IL-10, IL-13 as well as master regulator of Th2 differentiation
GATA3. INPAR-N association with these markers of Th2
differentiation was stronger than either complement system or T
cell activation alone, suggesting this newly inferred subnetwork
could be involved in CD4+ T cell differentiation. This might be
corroborated by the stronger than expected connectivity between
INPAR-N gene products, as this occurs when genes are involved
on a common mechanism. These results are strikingly corrobo-
rated by several other studies showing the involvement of multiple
INPAR-N genes in Th2 differentiation, e.g. Lck expression
mediates Th2 differentiation through effect on GATA3 [70].
Increased expression levels of CD81 [71] and impairment of FYN
expression are both implicated in Th2 differentiation [72].
Overall, our study confirms and extends previous work suggesting
the importance of complement system for normal T cell
differentiation [73] by showing its relevance for allergic sensitisa-
tion to pollen and delineating its involvement in CD4+ T cell
response to pollen allergen challenge.
This study contributes extensively to the characterization of
the gene expression signature of CD4+ T cells allergen response
and delineates a putative route for complement system modu-
lation of CD4+ T cell activation. INPAR analysis successfully
mapped the interaction between T cell activation and comple-
ment system by taking into consideration the interplay among
several pathways on coalescence and canalisation of function.
Although ultimately only clinical trials in humans can unequi-
vocally show the importance of a given mechanism or
intervention strategy in treatment and disease. The methodolo-
gies developed in this work can be applied to new problems to
perform global inferences from multiple experiments. The
integration of data at pathway level using the concept of
Pareto-efficiency and co-enrichment analysis can be applied to
other diseases to optimally identify the convergent biological
functions at the different levels of organization. In this context,
pathway level analyses using GSEA and MAGENTA allows the
use of all information within a dataset (GWAS or microarray)
rather than arbitrary assignment of a significance threshold and
concentrating on top hits. The method to identify coordination
between dysregulated pathways in disease context could be
applied to other problems since the underlying principles such as
enrichment for protein interactions, for expression correlations,
and for SNPs targeting disease protein hubs, are generalizable to
other complex diseases. The application of regression and gene
set correlation analysis to markers of the biological processes
related to the disease mechanism can also be extended to other
conditions to elicit the involvement of disease networks,
particularly when multilevel data is available. The proposed
drug target analysis is a useful in silico method to link gene
networks to in vivo physiology and pathophysiology. The
approach here proposed can bridge translational research in
animals and in vitro experiments, with human systemic response
to disease, allowing to elicit the impact in human physiology long
before more complex experiments, usually out of reach of most
basic research, are done. Consequentially, these methods have
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the potential to speeding up the process of identifying good
candidate interventions for personalised therapies in other disease
areas.
Supporting Information
Figure S1 Differential expression analysis of the dis-
covery and replication datasets. Histograms of the permu-
tation test t-statistics and p-value of the (A) Discovery and (B)
Replication dataset. Q-Q plot of the t-statistics in the (C)
Discovery and (D) Replication dataset. Correction for multi-
comparison using Storey-s q-value false discovery rate showing
approach to estimate probability of the null hypothesis as function
of the lambda parameter (E) Discovery and (F) Replication
datasets. The t-test distributions are symmetrically centred on zero
and the p-value histogram is enriched for the bracket of p-values
,0.05. The probability of the null hypothesis is greater than 0.6
for both datasets. Microarrays analysis produced no visible
artefacts.
(TIF)
Figure S2 Sensitivity analysis of the complement sys-
tem enrichment for genes differentially expressed.
Sensitivity of the complement system enrichment as a function
of the cut-offs on FDR and gene expression fold change. FDR cut-
offs range from 0.01–0.1 while fold change ranges 1–5. (A)
Enrichment odds ratio (B) Statististical significance of the
enrichment using the one side fisher exact test (C) Number of
significant genes withing the complement system pathway.
(TIF)
Figure S3 CD4+ T cells of cases and controls are
activated in response to pollen challenge. PCA scores plot
of the gene expression of (A) T cell activation, (B) Complement
system, (C) INPAR-N and (D) Genes differentially expressed in
response to pollen in the discovery dataset. MANOVA analysis of
the gene expression shows that the differences between cases and
controls stimulated with and without pollen is statistically
significant for all gene sets.
(TIF)
Figure S4 Gene expression of the Th2 and Th17
cytokine profiles shows significant differences between
cases and controls stimulated with and without pollen.
We applied a MANOVA analysis to the cytokines and master
regulator gene expression of cases and controls stimulated with
and without pollen. We show for the cytokine profile of each cell
subtype the log10 transformed p-value. The dashed lines
corresponds to a= 0.05 and aB = 0.05/4 = 0.0125.
(TIF)
Figure S5 Heat map of the spearman correlation
between genes of the Th2 cytokine profile + GATA3
Th2 master regulator with the genes interacting between
T cell activation and complement system.
(TIF)
Figure S6 Heat map of the multivariate regression
coefficient p-values showing the pattern of significant
associations between INPAR-N genes and Th2 cytokine
profile + GATA3 Th2 master regulator.
(TIF)
Figure S7 Spearman’s correlation between IL-13 pro-
tein level and gene expression of the pathway interaction
between T cell activation and complement system.
(TIF)
Figure S8 IL-13 protein level predictions vs. observa-
tions made with regression models fitted using leave one
out cross validation.
(TIF)
Figure S9 INPAR-N with nodes colour coded according
to the probability that a protein would be connected to
other INPAR-N genes (directly or indirectly) by chance.
The large majority of INPAR-N proteins are highly inter-
connected despite being selected from two distinct pathways,
suggesting their involvement on common mechanism.
(TIF)
Text S1 Table S1, Abbreviations and acronyms. Ta-
ble S2, Meta-analysis of KEGG pathways enrichment
showing consensus of GSEA and Hypergeometric test.
Complement system is one of the top pathways related
to immune system. Table S3, Meta-analysis of the GO
term enrichment showing consensus of GSEA and
Hypergeometric tests of the gene sets having more than
3% of genes differentially expressed. Table S4, Top 10
pathways associated with allergic grass pollen sensiti-
sation identified by GSEA analysis using MAGENTA.
Table S5, Gene ontology terms enrichment analysis
using DAVID. Table S6, KEGG pathway enrichment
analysis using DAVID. Table S7, Co-enrichment analy-
sis of gene expression and genetic variations using IPA
pathway definitions implicates complement system and
INPAR-N in the pathogenesis of allergy. Table S8,
Complement system genetic variations associated with
pollen allergic sensitisation ranked by adjusted p-value.
Table S9, Meta-Analysis of the complement system
genes differentially expressed in response to pollen in
atopic individuals. Table S10, Genes of the complement
system differentially expressed between atopic and
controls treated with pollen. Table S11, INPAR-N direct
and indirect proteins connectivity is statistically signif-
icant, suggesting their involvement on common mecha-
nism. Table S12, Disease network INPAR-N genetic
variations associated with pollen allergic sensitisation
ranked by adjusted p-value. Table S13, Meta-analysis of
the disease network (INPAR-N) genes expression show-
ing all transcripts available in both microarrays sorted
by meta-analysis p-value. Table S14, Biological coordi-
nation in atopic patients (cases) is disrupted in response
to pollen allergen (replication dataset). Table S15,
Subset of genes that interact between the complement
system and T cell activation (IngenuityH IPA). Meth-
ods S1.
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